An important question is whether MAP2K1-driven tumours align with conventional WHO melanomagenesis pathways, alongside BRAF, NRAS, and NF1 mutations, or pathway IV (Spitz), alongside kinase gene fusions and HRAS mutations. Here, NRAS is linked to neoplasm.